Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™

News   Sep 17, 2013

 
Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™
 
 
 

RELATED ARTICLES

Eppendorf Hosts Second Stem Cell Community Day in Duesseldorf

News

The event brings together experts from industry and academia to discuss recent trends, achievements, and challenges in bioprocessing technologies for stem cell research. The conference is organized by leading life science company Eppendorf AG.

READ MORE

Protein That Helps Keep Breast Cancer Dormant Identified

News

A protein kinase that stops breast cancer cells growing and spreading has been outlined in new research.

READ MORE

Anti-Inflammatory Pill Could Make Vaccines More Effective for the Elderly

News

By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE